ASCO Leaders Discuss Global Cancer Disparities and Local Solutions

“The biggest concern [in cancer care globally today] is equity,” said Monica Malik, MD, DNB, FASCO, of India.

On Monday, The ASCO Post published her interview—alongside two fellow International Affairs Committee leaders—laying out where global cancer care stands and where it is failing.

Malik, the committee’s immediate past chair, spoke with current Chair Piotr Rutkowski, MD, PhD, FASCO, of Poland, and Chair-Elect Matías Chacón, MD, of Argentina. Their conversation, The ASCO Post reported, centered on a widening gap in access, availability, and affordability as cancer incidence climbs worldwide—disparities sharpest in low- and middle-income countries.

Why it matters now: the numbers behind that gap are stark. Rutkowski cited projections of a 155% increase in cancer deaths in low-income countries by 2050, compared with 56% in high-income countries. The figures come from research he referenced in the interview, and they frame what ASCO’s international agenda is trying to slow.

The three leaders did not describe one uniform crisis. They described three different ones—and three different prescriptions.

India’s numbers, Argentina’s fragments

For Malik, the problem in India is scale. The sheer volume of patients is straining an already stretched health system, compounding disparities. Yet she pushed back on a common assumption: India has centers providing care comparable to leading institutions globally. The catch is geography and cost—much of that excellence sits in urban areas patients may not reach or afford.

She also rejected the idea that inequity belongs only to poorer nations. Low-resource areas exist inside high-income countries too, she told The ASCO Post.

Rutkowski’s concern runs through Central and Eastern Europe, where he catalogued a systems problem: limited health financing, weak screening uptake, delayed diagnoses, long waits for procedures, bureaucratic barriers to newer therapies, scarce clinical trials, and overburdened staff. Access varies considerably across the region, and between rural areas and major cities.

Chacón’s Argentina presents perhaps the most instructive paradox. The country has a highly trained oncology workforce, modern diagnostics, and clinical trial access. But care flows through three poorly coordinated subsystems—social security funds, private prepaid insurance, and the public sector.

“We have the expertise, we have infrastructure, but there is no coherency or equity in trying to solve these problems. Structural fragmentation of the health system is the main problem.”

Chacón calls his contribution to the gap a “deficit of implementation”—the distance between what evidence says is achievable and what health systems actually deliver. “There is not a difference in terms of knowledge,” he said. The trouble is translation.

Read together, the three accounts point to something the source frames well: inequity is not the absence of expertise. It is a question of where expertise sits, who can afford to reach it, and whether a health system can connect patients to care that already exists.

Where ASCO fits in

ASCO’s role, all three agreed, is connection. “When we think about ASCO, we think globally,” Rutkowski said, noting that several international initiatives have launched in recent years and will likely grow.

Chacón named three levers: adapting global evidence for lower-resource settings through resource-stratified guidelines, building the oncology workforce through the International Development and Education Award (IDEA), and democratizing knowledge via digital and open-access tools.

Malik stressed the network itself. “What is unique about ASCO is how it brings together diverse people who work with oncology,” she told The ASCO Post—medical, surgical, and radiation oncologists, pathologists, researchers, drug developers, and specialists in quality, palliative, and supportive care.

IDEA drew particular praise. The program pairs early-career oncologists from low- and middle-income countries with prominent ASCO mentors, and Rutkowski said that many current oncology leaders outside the United States are former IDEA fellows. “It has launched many careers and created leaders,” Malik said of the program, which she noted has helped hundreds of oncologists reach the global platform to collaborate and build mentorship.

Beyond IDEA, the leaders pointed to the Leadership Development Program with its reach into Asia-Pacific and Latin America, and the International Innovation Grant, which funds pragmatic projects in low- and middle-income countries.

Malik was candid about what those grants fund: not always cutting-edge drug development, but work with substantial implications for care in those settings. Rutkowski added that expanding clinical trial equity in such countries is a long-term goal, supported by clinical cancer research workshops in his region.

Regional councils—covering Asia-Pacific, Latin America, Sub-Saharan Africa, and Central and Eastern Europe—may be the clearest mechanism for keeping ASCO’s efforts locally grounded.

All three leaders endorsed them, with Chacón calling them “one of the most important things that [the organization] provides to the world right now.” Rutkowski went further, suggesting councils could trade solutions across regions; he cited the molecular tumor board program run by the Central and Eastern Europe Council as one exportable success.

Other initiatives with reach include the Quality Oncology Practice Initiative Certification Program, global courses, and ASCO Breakthrough meetings. “More than 170 countries are attending ASCO meetings,” Rutkowski said, “so, generally, it means that knowledge is dispersed everywhere.”

Lessons that travel both ways

The interview’s sharpest insight may be its reversal of the usual direction of medical philanthropy. The leaders argued that innovations born in resource-constrained settings can teach wealthier health systems something.

Malik pointed to Indian research on low-dose immunotherapy and hypofractionated radiation. If those approaches prove non-inferior while cutting costs, the implications stretch far beyond India.

Malik said that if research proves that less is enough or not inferior, countries like India and other low- and middle-income countries can and are taking the lead in driving these kinds of innovative practices.

Rutkowski offered digitalization as Central and Eastern Europe’s quiet export. In Estonia, he said, almost everything is digitalized; in Latvia, he accessed a patient’s examinations nationwide with a single code. Those systems, built out during the COVID-19 pandemic, remain in daily use.

And Chacón described an Argentine cervical cancer screening program in which community health workers offered HPV DNA self-collection during routine home visits—an approach he suggested could adapt elsewhere, including in wealthier countries struggling with screening uptake.

ASCO’s own framing of the moment came from then-President Eric J. Small, MD, FASCO, whose Presidential Address at the 2026 ASCO Annual Meeting called on the oncology community to translate knowledge “across languages, cultures, geographies, resource availability, and practice sites, so that all patients can benefit.”

Whether that translation happens—and how fast—will decide whether that 155% projection holds. The committee’s new leadership lineup, with Chacón waiting in the wings, suggests the work of answering it has only just changed hands.

Photo of author

Newsroom

Newsroom at Archyde.

18-Country Study: Loneliness Shows Stronger Mental Disorder Association Than Isolation

Yaxel Lendeborg Tops TalkBasket.net Rookie Ladder; Cameron Boozer Climbs to No. 2